The efficacy of L-carnitine addition in treatment of major depressive disorder

Comparing the efficacy of L-carnitine and sertraline compared with sertraline alone on severity of depression in patients with major depressive disorder: A double blinded randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150630022991N15

Enrollment

Registered

2021-02-26

Start date

2021-02-08

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Major depressive disorder. Condition 2: Major depressive disorder. Major depressive disorder, single episode Major depressive disorder, recurrent severe without psychotic features

Interventions

Intervention 1: Intervention group: will receive 1000 milligram of L-carnitine oral capsule daily made by Vana-Darougostar Pharmaceutical Company along with 100 milligram of sertraline made by Tehran-

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of major depressive disorder based on diagnostic and statistical manual of mental disorders, 5th edition (DSM-5) through a psychiatrist clinical interview Age 18 years and over

Exclusion criteria

Exclusion criteria: Previous history of high mood (mania and/ or hypomania) Presence of dementia Cognitive dysfunction Acute psychiatric disorders based on the opinion of a psychiatrist Serious somatic disorders Substance dependence, except cigarettes and caffeine Consumption of drugs that makes the incidence of depression in the patient

Design outcomes

Primary

Measure	Time frame
Severity of depression. Timepoint: At baseline, the third and sixth weeks after the treatment. Method of measurement: Based on Beck depression scale.	—

Secondary

Measure	Time frame
Drug side effects. Timepoint: At baseline, the third and sixth weeks after the treatment. Method of measurement: Medical visit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSussan Moudi, MD

Babol University of Medical Sciences

sussan.mouodi@gmail.com+98 11 3219 7667

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026